Nuwellis (NASDAQ:NUWE) Upgraded at Roth Capital

Roth Capital upgraded shares of Nuwellis (NASDAQ:NUWE) to a strong-buy rating in a report published on Monday morning, Zacks.com reports. Roth Capital also issued estimates for Nuwellis’ Q2 2024 earnings at ($9.49) EPS, Q3 2024 earnings at ($0.67) EPS, Q4 2024 earnings at ($0.48) EPS, FY2024 earnings at ($7.00) EPS, FY2025 earnings at ($1.58) EPS, FY2026 earnings at ($0.06) EPS, FY2027 earnings at $1.58 EPS and FY2028 earnings at $3.54 EPS.

Separately, Roth Mkm initiated coverage on shares of Nuwellis in a research report on Monday. They set a buy rating and a $17.00 target price on the stock.

Nuwellis Stock Down 2.5 %

NASDAQ NUWE opened at $2.76 on Monday. The firm has a market cap of $1.79 million, a PE ratio of -0.01 and a beta of 0.44. The company has a 50 day moving average price of $5.72 and a 200 day moving average price of $11.24. Nuwellis has a 52 week low of $2.19 and a 52 week high of $92.75.

Nuwellis (NASDAQ:NUWE) last released its earnings results on Tuesday, May 7th. The company reported ($21.00) earnings per share for the quarter. The company had revenue of $1.86 million for the quarter. Nuwellis had a negative return on equity of 316.90% and a negative net margin of 202.97%. On average, equities research analysts anticipate that Nuwellis will post -7 earnings per share for the current fiscal year.

About Nuwellis

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.